A cardiac myosin ATPase inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Mavacamten

Item No. 19216

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
3-(1-methylethyl)-6-[[(1S)-1-phenylethyl]amino]-2,4(1H,3H)-pyrimidinedione
CAS Number
1642288-47-8
Synonyms
  • MYK-461
  • SAR439152
Molecular Formula
C15H19N3O2
Formula Weight
273.3
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 33 mg/mlDMF:PBS(pH 7.2)(1:1): 0.5 mg/mlDMSO: 20 mg/mlEthanol: 1 mg/ml
λmax
267 nm
SMILES
O=C1N(C(C)C)C(NC(N[C@@H](C)C2=CC=CC=C2)=C1)=O
InChi Code
InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
InChi Key
RLCLASQCAPXVLM-NSHDSACASA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $69

    Add

    5 mg

    $167

    Add

    10 mg

    $297

    Add
    Product Description

    Mavacamten is an orally bioavailable inhibitor of cardiac myosin ATPase (IC50 = 0.3 µM in purified bovine myosin S1).1 It is selective for cardiac myosin over skeletal myosin (IC50 = 4.7 µM) and does not induce skeletal muscle impairments. It slows the rate of ATPase activity in both murine and bovine myofibrils, which are α- and β-myosin-rich, respectively, by reducing the rate of phosphate release during the myosin power stroke. In transgenic mouse models of hypertrophic cardiomyopathy, mavacamten reduces cardiac contractility, prevents left ventricular hypertrophy, and reverses pathologic remodeling. In cats, it relieves left ventricular outflow tract obstruction.2 Formulations containing mavacamten have been used for the treatment of symptomatic hypertrophic cardiomyopathy in humans and cats.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Green, E.M., Wakimoto, H., Anderson, R.L., et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351(6273), 617-623 (2016).

    2. Stern, J.A., Markova, S., Ueda, Y., et al. A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy. PLoS One 11(12), e0168407 (2016).